TKD-functionalized smart micelles targeting mHSP70 show promise for precision breast cancer therapy

Breast cancer remains the most frequently diagnosed malignancy among women, characterized by high recurrence, therapeutic resistance, and significant molecular heterogeneity. Current standard-of-care often falls short in aggressive subtypes due to these challenges. Membrane-bound heat shock protein 70 (mHSP70) has emerged as a tumor-selective biomarker, exhibiting elevated expression in aggressive breast cancer with minimal presence in normal tissues. Functionally, mHSP70 contributes to immune evasion, metastatic progression, and chemoresistance, making it a compelling therapeutic target for novel interventions.

This review critically evaluated the biological role of membrane-bound heat shock protein 70 (mHSP70) in breast cancer, assessing its diagnostic and therapeutic implications. It specifically examined the translational potential of TKD peptide-guided nanocarriers, synthesizing findings from preclinical investigations. The authors analyzed how these smart micelles could enhance tumor penetration, reverse multidrug resistance, and elicit anti-tumor immune responses, focusing on strategies to optimize pharmacokinetics and immunological compatibility for successful clinical translation. The review aimed to integrate precision nanotechnology with mHSP70-targeted therapy.

The review identified mHSP70 as a robust tumor-selective biomarker, highly expressed in aggressive breast cancer subtypes and functionally implicated in immune evasion, metastatic progression, and chemoresistance. The 14-mer TKD peptide (TKDNNLGRFELSG) was highlighted for its high-affinity binding to mHSP70, enabling targeted drug delivery to HSP70-positive malignant cells. Preclinical investigations, as summarized by the review, consistently demonstrate that TKD peptide-functionalized nanocarriers offer significant therapeutic advantages. These include enhanced tumor penetration, a crucial factor in overcoming drug delivery barriers, and the ability to reverse multidrug resistance, a major cause of treatment failure. Furthermore, these nanocarriers were shown to elicit anti-tumor immune responses, suggesting a multi-pronged attack against cancer. The integration of precision nanotechnology with mHSP70-targeted therapy represents a potentially promising approach to overcoming treatment resistance and improving outcomes in metastatic breast cancer. However, the review emphasized that successful clinical translation requires optimization of pharmacokinetics, immunological compatibility, and in vivo stability.

TKD peptide-functionalized nanocarriers enhance tumor penetration, reverse multidrug resistance, and elicit anti-tumor immune responses in preclinical models.